Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

@article{Middeke2013OutcomeOP,
  title={Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.},
  author={Jan M Middeke and Min Fang and Jan Jacob Cornelissen and Brigitte Mohr and Frederick R Appelbaum and Michael Stadler and Jaime Sanz and Herrad Baurmann and Gesine Bug and Kerstin Schaefer-Eckart and Ute Hegenbart and Tilmann Bochtler and Christoph R{\"o}llig and Friedrich Stoelzel and Roland B. Walter and Gerhard Ehninger and Martin Bornhaeuser and Bob L{\"o}wenberg and Johannes Schetelig},
  journal={Blood},
  year={2013},
  volume={123 19},
  pages={
          2960-7
        }
}
Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl(17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

JJ Cornelissen, D Breems, WL van Putten
  • J Clin Oncol
  • 2012
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

H Döhner, EH Estey, S Amadori
  • 2010
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Posttransplant maintenance with the deacetylase inhibitor panobinostat in patients with high-risk AML or MDS: results of the phase I part of the Panobest Trial [abstract

G Bug, A Burchert, N Kroeger
  • ASH Annual Meeting Abstracts
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Study Alliance Leukaemia (SAL). Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia

B Mohr, J Schetelig, K Schäfer-Eckart
  • Br J Haematol
  • 2013
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL